Literature DB >> 33275166

Fatigue and brain arousal in patients with major depressive disorder.

Galina Surova1,2, Christine Ulke3,4, Frank Martin Schmidt3, Tilman Hensch3,5, Christian Sander3, Ulrich Hegerl4,6.   

Abstract

Fatigue is considered a key symptom of major depressive disorder (MDD), yet the term lacks specificity. It can denote a state of increased sleepiness and lack of drive (i.e., downregulated arousal) as well as a state of high inner tension and inhibition of drive with long sleep onset latencies (i.e., upregulated arousal), the latter typically found in depression. It has been proposed to differentiate fatigue along the dimension of brain arousal. We investigated whether such stratification within a group of MDD patients would reveal a subgroup with distinct clinical features. Using an automatic classification of EEG vigilance stages, an arousal stability score was calculated for 15-min resting EEGs of 102 MDD patients with fatigue. 23.5% of the patients showed signs of hypoarousal with EEG patterns indicating drowsiness or sleep; this hypoaroused subgroup was compared with remaining patients (non-hypoaroused subgroup) concerning self-rated measures of depressive symptoms, sleepiness, and sleep. The hypoaroused subgroup scored higher on the Beck Depression Inventory items "loss of energy" (Z = - 2.13, p = 0.033; ɳ2 = 0.044, 90% CI 0.003-0.128) and "concentration difficulty" (Z = - 2.40, p = 0.017; ɳ2 = 0.056, 90% CI 0.009-0.139), and reported higher trait and state sleepiness (p < 0.05) as compared to the non-hypoaroused group. The non-hypoaroused subgroup, in contrast, reported more frequently the presence of suicidal ideation (Chi2 = 3.81, p = 0.051; ɳ2 = 0.037, 90% CI 0.0008-0.126). In this study, we found some evidence that stratifying fatigued MDD patients by arousal may lead to subgroups that are pathophysiologically and clinically more homogeneous. Brain arousal may be a worth while target in clinical research for better understanding the mechanisms underlying suicidal tendencies and to improve treatment response.

Entities:  

Keywords:  Brain arousal regulation; Depression; EEG; Fatigue; Neurophysiology

Year:  2020        PMID: 33275166      PMCID: PMC7981331          DOI: 10.1007/s00406-020-01216-w

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  57 in total

1.  Excessive daytime sleepiness and fatigue in depressed patients and therapeutic response of a sedating antidepressant.

Authors:  Jianhua Shen; Naheed Hossain; David L Streiner; Aruu V Ravindran; Xuehua Wang; Prativa Deb; Xin Huang; Frank Sun; Colin M Shapiro
Journal:  J Affect Disord       Date:  2011-05-25       Impact factor: 4.839

Review 2.  Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors.

Authors:  George I Papakostas; David J Nutt; Lindsay A Hallett; Vivian L Tucker; Alok Krishen; Maurizio Fava
Journal:  Biol Psychiatry       Date:  2006-08-24       Impact factor: 13.382

Review 3.  Objective measurement of sleep, heart rate, heart rate variability, and physical activity in suicidality: A systematic review.

Authors:  Gu Eon Kang; Michelle A Patriquin; Hung Nguyen; Hyuntaek Oh; Katrina A Rufino; Eric A Storch; Bella Schanzer; Sanjay J Mathew; Ramiro Salas; Bijan Najafi
Journal:  J Affect Disord       Date:  2020-05-18       Impact factor: 4.839

Review 4.  Neuroendocrine and immune contributors to fatigue.

Authors:  Marni N Silverman; Christine M Heim; Urs M Nater; Andrea H Marques; Esther M Sternberg
Journal:  PM R       Date:  2010-05       Impact factor: 2.298

5.  Why do stimulants not work in typical depression?

Authors:  Ulrich Hegerl; Tilman Hensch
Journal:  Aust N Z J Psychiatry       Date:  2016-11-02       Impact factor: 5.744

6.  Early report on brain arousal regulation in manic vs depressive episodes in bipolar disorder.

Authors:  Dirk Alexander Wittekind; Janek Spada; Alexander Gross; Tilman Hensch; Philippe Jawinski; Christine Ulke; Christian Sander; Ulrich Hegerl
Journal:  Bipolar Disord       Date:  2016-09       Impact factor: 6.744

7.  Fatigue and sleep disturbance in patients with cancer, patients with clinical depression, and community-dwelling adults.

Authors:  Karen O Anderson; Carl J Getto; Tito R Mendoza; Stephen N Palmer; Xin Shelley Wang; Cielito C Reyes-Gibby; Charles S Cleeland
Journal:  J Pain Symptom Manage       Date:  2003-04       Impact factor: 3.612

Review 8.  Fatigue in Patients with Major Depressive Disorder: Prevalence, Burden and Pharmacological Approaches to Management.

Authors:  Helia Ghanean; Amanda K Ceniti; Sidney H Kennedy
Journal:  CNS Drugs       Date:  2018-01       Impact factor: 5.749

9.  The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue.

Authors:  E M Smets; B Garssen; B Bonke; J C De Haes
Journal:  J Psychosom Res       Date:  1995-04       Impact factor: 3.006

Review 10.  Candidate Biomarkers of Suicide Crisis Syndrome: What to Test Next? A Concept Paper.

Authors:  Raffaella Calati; Charles B Nemeroff; Jorge Lopez-Castroman; Lisa J Cohen; Igor Galynker
Journal:  Int J Neuropsychopharmacol       Date:  2020-04-21       Impact factor: 5.176

View more
  3 in total

Review 1.  EEG Neurofeedback for Anxiety Disorders and Post-Traumatic Stress Disorders: A Blueprint for a Promising Brain-Based Therapy.

Authors:  J A Micoulaud-Franchi; C Jeunet; A Pelissolo; T Ros
Journal:  Curr Psychiatry Rep       Date:  2021-10-29       Impact factor: 5.285

2.  Effects of mindfulness-based intervention programs on sleep among people with common mental disorders: A systematic review and meta-analysis.

Authors:  Sunny Ho-Wan Chan; Danielle Lui; Hazel Chan; Kelly Sum; Ava Cheung; Hayley Yip; Chong Ho Yu
Journal:  World J Psychiatry       Date:  2022-04-19

3.  Moving toward a process-oriented perspective in the personalized treatment of depression.

Authors:  Johannes Kopf-Beck; Julia Fietz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-03-05       Impact factor: 5.270

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.